Here, we use mouse models of melanoma with defective STING signaling, either in the host immune component or in the tumor itself, to show that a DNA methyltransferase inhibitor can rescue tumor cell-intrinsic STING signaling dysfunction in vivo and subsequently induce greater tumor regression through a CD8+ T cell-dependent mechanism. Here, STING1 is linked to melanoma.